Attenuation of the early anterior negativity of median nerve somatosensory evoked potential in the MPTP-treated monkey

Median nerve somatosensory evoked potentials (SEP) were recorded in 7 Cynomolgus monkeys, before and after the administration of N-Methyl 1,4 Phenyl 1,2,3,6 tetrahydropiridine (MPTP), a neurotoxin which induces a parkinsonian syndrome in primates. Following MPTP administration, the amplitude of the...

Full description

Saved in:
Bibliographic Details
Published inNeurophysiologie clinique Vol. 20; no. 4; p. 283
Main Authors Onofrj, M, Ghilardi, M F, Basciani, M, Martinez-Tica, J, Glover, A
Format Journal Article
LanguageEnglish
Published France 01.10.1990
Subjects
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology
Animals
Electric Stimulation
Evoked Potentials, Somatosensory - drug effects
Frontal Lobe - physiology
Injections, Intravenous
Ketamine - pharmacology
Macaca fascicularis
Median Nerve - drug effects
Parietal Lobe - physiology
Parkinson Disease, Secondary - chemically induced
Parkinson Disease, Secondary - physiopathology
Online AccessGet more information

Cover

More Information
Summary:Median nerve somatosensory evoked potentials (SEP) were recorded in 7 Cynomolgus monkeys, before and after the administration of N-Methyl 1,4 Phenyl 1,2,3,6 tetrahydropiridine (MPTP), a neurotoxin which induces a parkinsonian syndrome in primates. Following MPTP administration, the amplitude of the negative component recorded at 15 ms over the frontal derivations (N15) decreased by 70% or more. This amplitude reduction was not modified by administration of dopamine precursors. These findings shed light on recent findings in human parkinsonian patients.
ISSN:0987-7053
DOI:10.1016/S0987-7053(05)80118-2